Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-09

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-09 — Deep Dive: Hypertension in Pregnancy
Tier: Tier 3 — Clinical Vignettes

1. A 26-year-old woman at 38 weeks gestation with no prior history of hypertension presents with BP 172/114 mmHg, severe headache, and 3+ proteinuria on dipstick. She has never had prenatal care. Her platelet count is 74,000/mcL, AST is 186 U/L (ULN 40), and LDH is 920 U/L. Peripheral smear shows schistocytes. Her creatinine is 1.4 mg/dL. Which of the following correctly identifies the diagnosis and the complete immediate pharmacological management?

A) This is gestational hypertension with incidental thrombocytopenia from iron deficiency anemia — start labetalol 100 mg orally and discharge with outpatient follow-up in 48 hours; the thrombocytopenia and liver enzyme elevation are unrelated to the hypertension.
B) This is preeclampsia without severe features — start oral methyldopa 500 mg and reassess in 4 hours; the laboratory abnormalities are mild and do not require urgent intervention or magnesium sulfate at this stage.
C) This is preeclampsia with severe features complicated by HELLP syndrome — immediate pharmacological management requires: IV labetalol 20 mg over 2 minutes for acute BP control (escalate per protocol if BP remains ≥160/110 mmHg); IV magnesium sulfate 4–6 g loading dose over 15–20 minutes followed by 1–2 g/hour maintenance for seizure prophylaxis; delivery is the definitive treatment and is indicated at 38 weeks with HELLP; calcium gluconate 1 g IV must be at the bedside; platelet transfusion threshold is below 50,000/mcL for cesarean; monitor deep tendon reflexes, respiratory rate, and urine output hourly.
D) This is eclampsia — start magnesium sulfate 4 g IV over 5 minutes and administer phenytoin 15 mg/kg IV simultaneously; BP management is deferred until after seizure prophylaxis is fully established.
E) This is HELLP syndrome without preeclampsia — her BP elevation is a stress response to pain and will resolve with analgesia; dexamethasone 10 mg IV is the primary pharmacological intervention for HELLP; antihypertensives and magnesium sulfate are not indicated when BP elevation is stress-related.

ANSWER: C

Rationale:

This patient has preeclampsia with severe features complicated by HELLP syndrome. The HELLP diagnosis is established by: hemolysis (LDH 920 U/L, elevated; schistocytes on smear), elevated liver enzymes (AST 186 U/L — approximately 4.5x ULN), and low platelets (74,000/mcL — below the 100,000/mcL threshold, qualifying as severe features of preeclampsia). The BP of 172/114 mmHg meets the severe-range threshold (≥160/110 mmHg). The creatinine of 1.4 mg/dL exceeds the 1.1 mg/dL severe feature threshold. She has multiple concurrent severe features. The complete immediate pharmacological management requires: IV labetalol for acute BP control (starting at 20 mg IV over 2 minutes with escalation per protocol); IV magnesium sulfate loading dose followed by continuous maintenance infusion for seizure prophylaxis (mandatory in severe preeclampsia); delivery planning at 38 weeks (no indication to defer delivery in a term patient with HELLP); platelet transfusion threshold of 50,000/mcL for surgical delivery planning; and continuous clinical monitoring.

Option A: Option A is incorrect because the combination of hypertension after 20 weeks, 3+ proteinuria, thrombocytopenia (74,000/mcL), elevated liver enzymes, elevated LDH, and schistocytes is not iron deficiency anemia — this is HELLP syndrome complicating preeclampsia with severe features; discharging this patient is clinically dangerous.
Option B: Option B is incorrect because this presentation has multiple severe features including HELLP and is not preeclampsia without severe features — oral methyldopa is too slow for acute severe BP control and magnesium sulfate is mandatory with these findings.
Option D: Option D is incorrect because eclampsia requires a new-onset grand mal seizure — this patient has not had a seizure; the diagnosis is preeclampsia with severe features and HELLP; and phenytoin simultaneously with magnesium is not the standard approach.
Option E: Option E is incorrect because HELLP syndrome in the context of severe hypertension and proteinuria does not occur independently of preeclampsia in this presentation; BP elevation is not attributed to stress without further evidence; and dexamethasone alone without antihypertensives and magnesium sulfate is inadequate and dangerous management.

2. A 33-year-old woman with longstanding type 1 diabetes (diagnosed age 8) and CKD stage 2 (eGFR 74, UACR 340 mg/g) at 18 weeks gestation presents for a routine prenatal visit. She switched from ramipril to labetalol 100 mg twice daily before conception. Her BP today is 134/86 mmHg. Her nephrologist asks whether any additional pharmacological renoprotection can be offered during pregnancy given that RAAS inhibition has been stopped. Which of the following best describes what can and cannot be offered pharmacologically during pregnancy for her renal protection?

A) During pregnancy, dedicated renoprotection beyond BP control is severely pharmacologically limited — RAAS inhibitors (the primary evidence-based renoprotective agents) are absolutely contraindicated; SGLT2 inhibitors are not approved in pregnancy; there is no equivalent renoprotective pharmacological substitute during pregnancy; close monitoring of creatinine, UACR, and BP is the management approach; BP control with labetalol and nifedipine (targeting the pregnancy-appropriate range) reduces the systemic hypertensive contribution to renal injury; RAAS inhibition should be reinstated immediately postpartum (captopril or enalapril are breastfeeding-compatible) for continued renoprotection.
B) Spironolactone can be added during pregnancy to provide renoprotection — its antialdosterone effect reduces proteinuria through mechanisms independent of fetal RAAS effects; at doses below 25 mg daily the anti-androgenic effects on the male fetus are negligible and acceptable.
C) Dapagliflozin can be continued during pregnancy at half dose (5 mg daily) — the renoprotective indication for SGLT2 inhibitors in type 1 diabetic CKD creates a medical necessity exception; at 5 mg the glucose-lowering effect is minimal, reducing the risk of euglycemic DKA in pregnancy.
D) Finerenone 10 mg daily can be added — as a non-steroidal MRA, finerenone does not bind androgen receptors and is therefore safe in pregnancy without any anti-androgenic fetal risk; it provides the renal anti-fibrotic benefit of MR blockade to compensate for the loss of RAAS inhibition.
E) Losartan at 25 mg daily can be used during pregnancy for renoprotection in type 1 diabetic CKD — the fetal RAAS toxicity of ARBs only applies at standard antihypertensive doses; at 25 mg daily the renoprotective efferent arteriolar dilation occurs through a subthreshold RAAS inhibition mechanism that does not affect fetal kidney development.

ANSWER: A

Rationale:

This is one of the most pharmacologically challenging situations in obstetric medicine — a woman with progressive diabetic nephropathy who requires RAAS inhibition for renoprotection but must forgo it during pregnancy. The pharmacological reality is stark: RAAS inhibitors are absolutely contraindicated in all trimesters; SGLT2 inhibitors are not approved in pregnancy (contraindicated before conception through delivery); finerenone has insufficient human safety data and is avoided; spironolactone is avoided due to anti-androgenic effects; there is no pharmacological equivalent to RAAS inhibition for renoprotection that is safe during pregnancy. The practical approach is: optimize BP control within the pregnancy-appropriate target range (BP control reduces the systemic hypertensive component of renal injury, though it does not provide the specific intraglomerular pressure-reducing, antiproteinuric mechanism of ACEi or ARBs); monitor creatinine and UACR closely throughout pregnancy for accelerated progression; counsel the patient about the expected UACR rise and possible eGFR decline during pregnancy without RAAS inhibition; and reinstate captopril or enalapril immediately postpartum given their breastfeeding compatibility.

Option B: Option B is incorrect because spironolactone is specifically avoided in pregnancy due to its anti-androgenic properties — concern for feminization of male fetuses exists from animal data; and at any dose, the anti-androgenic risk is not eliminated by dose reduction to 25 mg.
Option C: Option C is incorrect because SGLT2 inhibitors are not approved in pregnancy and there is no established safe dose during pregnancy — half-dose does not eliminate the concern about SGLT2 inhibition during fetal renal tubular development.
Option D: Option D is incorrect because finerenone's lack of androgen receptor binding does not make it safe in pregnancy — there is insufficient human safety data for finerenone in pregnancy and it should be avoided; the absence of anti-androgenic activity is a favorable property but does not establish pregnancy safety.
Option E: Option E is incorrect because ARBs are absolutely contraindicated at any dose — the RAAS-dependent fetal renal developmental toxicity is not dose-dependent in a way that produces a safe sub-threshold dose; efferent arteriolar dilation sufficient for renoprotection would by definition inhibit the fetal RAAS.

3. A 29-year-old woman at 31 weeks gestation is brought to the obstetric unit with a BP of 188/122 mmHg and a generalized tonic-clonic seizure that has self-terminated. She was normotensive at her last prenatal visit 2 weeks ago. She has 3+ proteinuria. Fetal heart rate monitoring shows a reactive tracing. Which of the following correctly describes the pharmacological priorities in the first 60 minutes?

A) Priority 1: IV phenytoin 15 mg/kg over 30 minutes for seizure prevention; Priority 2: observation only for BP as a single seizure does not increase stroke risk; Priority 3: corticosteroids for fetal lung maturity.
B) Priority 1: IV hydralazine 5 mg bolus for BP; Priority 2: oral diazepam 10 mg for seizure recurrence prevention; Priority 3: magnesium sulfate to be started after BP is below 140/90 mmHg.
C) Priority 1: CT head immediately to exclude intracranial hemorrhage before any pharmacological intervention; Priority 2: IV labetalol after CT confirms no hemorrhage; Priority 3: magnesium sulfate after BP is controlled.
D) Priority 1: IV magnesium sulfate 4–6 g loading dose over 15–20 minutes — this eclamptic seizure mandates immediate magnesium for recurrence prevention; Priority 2: IV labetalol 20 mg over 2 minutes (or oral nifedipine IR 10 mg swallowed) simultaneously for acute severe BP control — BP of 188/122 mmHg is a stroke emergency requiring treatment within 30–60 minutes; both interventions proceed simultaneously, not sequentially; Priority 3: corticosteroids for fetal lung maturity at 31 weeks; plan for delivery after maternal stabilization.
E) Priority 1: IV labetalol 80 mg bolus for immediate BP reduction; Priority 2: magnesium sulfate 10 g loading dose for seizure; Priority 3: emergency cesarean section within 30 minutes regardless of maternal stabilization status.

ANSWER: D

Rationale:

Eclampsia with severe-range hypertension requires simultaneous management of two pharmacological emergencies — neither can wait for the other to be completed. Priority 1 is IV magnesium sulfate: a loading dose of 4–6 g IV over 15–20 minutes is the definitive treatment for the eclamptic seizure and prevents recurrence; this must be started immediately. Priority 2 is acute BP control, proceeding simultaneously: the BP of 188/122 mmHg represents an extreme stroke emergency — at this level, every minute of delayed treatment increases hemorrhagic stroke risk; IV labetalol 20 mg over 2 minutes is the first dose, with escalation per protocol if BP does not respond; oral nifedipine IR 10 mg swallowed is an alternative if IV access is not yet secured. Corticosteroids (betamethasone) at 31 weeks are indicated to accelerate fetal lung maturity before anticipated preterm delivery. Delivery planning proceeds after maternal stabilization. The critical pharmacological principle is that BP treatment and magnesium sulfate are initiated simultaneously — the concept of "controlling BP first, then starting magnesium" delays seizure prophylaxis, and "starting magnesium first, then treating BP" allows the stroke risk to persist.

Option A: Option A is incorrect because phenytoin is not preferred over magnesium sulfate for eclampsia; observation only for BP at 188/122 mmHg is clinically unacceptable.
Option B: Option B is incorrect because oral diazepam is not the agent of choice for eclampsia recurrence prevention — magnesium sulfate is; and deferring magnesium until BP is below 140/90 mmHg would delay seizure prophylaxis unacceptably.
Option C: Option C is incorrect because CT head is not the immediate first pharmacological priority in a woman with known preeclampsia and new-onset seizure at 31 weeks — the diagnosis of eclampsia is clinical; delaying magnesium and BP treatment for CT imaging is dangerous and would be reserved for atypical presentations (seizure without hypertension, late postpartum onset, focal neurological signs suggesting alternative etiology).
Option E: Option E is incorrect because the IV labetalol starting dose is 20 mg (not 80 mg — 80 mg is a later escalation dose in the protocol, not the initial dose) and the magnesium loading dose is 4–6 g (not 10 g); and emergency cesarean within 30 minutes without maternal stabilization is not appropriate — maternal stabilization with BP control and seizure prophylaxis takes priority before delivery.

4. A woman at 28 weeks gestation with preeclampsia is being managed expectantly. She is on labetalol 200 mg three times daily and long-acting nifedipine 60 mg daily. BP is 142/88 mmHg. Magnesium sulfate is running at 1.5 g/hour maintenance. At rounds, a nurse reports the patellar reflex is 1+ (reduced but present) and the respiratory rate is 16. Serum magnesium level checked 30 minutes ago is 5.8 mEq/L. Which of the following best describes the clinical assessment and management?

A) The magnesium level of 5.8 mEq/L and reduced patellar reflex indicate serious toxicity requiring immediate calcium gluconate 1 g IV and complete cessation of the magnesium infusion; do not restart magnesium for at least 24 hours.
B) The clinical picture is consistent with therapeutic magnesium levels — a level of 5.8 mEq/L is within the therapeutic range of 4–7 mEq/L; a patellar reflex of 1+ (present, though reduced) is not the same as absent deep tendon reflexes; respiratory rate of 16 is above the 12 breaths per minute threshold; no intervention is required beyond continuing the current monitoring protocol hourly and adjusting the infusion only if patellar reflexes become absent or respiratory rate falls below 12.
C) The magnesium level is subtherapeutic — 5.8 mEq/L is below the seizure prophylaxis threshold; the infusion rate should be increased to 3 g/hour to achieve adequate therapeutic levels; the reduced patellar reflex at 1+ is a normal finding in pregnancy.
D) The current status requires a precautionary infusion rate reduction — any reduction in deep tendon reflexes at this stage indicates approaching toxicity and the infusion should be reduced from 1.5 g/hour to 0.5 g/hour preemptively; the magnesium level will need to be rechecked in 4 hours.
E) The combination of labetalol, nifedipine, and magnesium constitutes a dangerous triple calcium-blocking regimen — all three agents block intracellular calcium through different mechanisms; all three agents should be stopped immediately and BP managed with methyldopa as the only safe antihypertensive in this setting.

ANSWER: B

Rationale:

The clinical picture is entirely consistent with therapeutic magnesium management. A serum magnesium level of 5.8 mEq/L falls within the established therapeutic range of 4–7 mEq/L for seizure prophylaxis in preeclampsia. A patellar reflex of 1+ is reduced from normal (2+) but is importantly present — the toxicity threshold is loss of deep tendon reflexes (absent, 0+), not simply reduced reflexes; a 1+ reflex indicates the patient is within or approaching the upper therapeutic range, which is expected at 5.8 mEq/L. A respiratory rate of 16 breaths per minute is above the 12 breaths per minute safety threshold. The correct management is to continue the current monitoring protocol — hourly patellar reflex assessment, respiratory rate, and urine output — without changing the infusion rate. Intervention is needed if: patellar reflexes become absent (reduce or hold infusion, recheck level), respiratory rate falls below 12 (hold infusion, give calcium gluconate if respiratory depression is significant), or clinical toxicity develops.

Option A: Option A is incorrect because the current clinical picture — level within therapeutic range, reflexes present (1+), adequate respiratory rate — does not meet the threshold for calcium gluconate administration or magnesium cessation; administering the antidote preemptively when the patient is within therapeutic range would reverse seizure prophylaxis unnecessarily.
Option C: Option C is incorrect because 5.8 mEq/L is not subtherapeutic — it is within the 4–7 mEq/L therapeutic range; increasing the infusion to 3 g/hour at an already-therapeutic level would risk pushing the patient into the toxic range.
Option D: Option D is incorrect because a 1+ patellar reflex does not constitute approaching toxicity requiring preemptive infusion reduction — the clinical trigger for reducing the infusion is absent reflexes (0+), not reduced reflexes (1+).
Option E: Option E is incorrect because labetalol does not block intracellular calcium channels — it is an adrenoceptor blocker; the "triple calcium-blocking" characterization of labetalol plus nifedipine plus magnesium misrepresents labetalol's mechanism; and stopping all medications would leave both the BP uncontrolled and seizure prophylaxis absent.

5. A 38-year-old woman (G3P2) with a history of preeclampsia in both prior pregnancies presents at 10 weeks gestation for prenatal care. She is normotensive (BP 118/72 mmHg) and not on any medications. Her obstetrician wants to discuss preeclampsia prevention. Which pharmacological intervention is most strongly evidence-based, and when should it be started?

A) Prophylactic magnesium sulfate — oral magnesium glycinate 400 mg daily started at 10 weeks reduces the risk of preeclampsia by preventing the neurological hyperexcitability that initiates the endothelial dysfunction cascade; it has been shown to reduce preeclampsia incidence by 35% in high-risk women.
B) Heparin prophylaxis — low-molecular-weight heparin 40 mg daily subcutaneously prevents the placental microthrombi that obstruct spiral artery remodeling in preeclampsia; the thromboprophylactic mechanism addresses the primary pathological process.
C) Pravastatin 20 mg daily — statins improve endothelial function and reduce sFlt-1 production; statin use in high-risk women beginning at 12 weeks has been shown in randomized trials to reduce preeclampsia incidence by 40%.
D) Supplemental calcium 1.5–2 g daily — calcium supplementation specifically reduces the risk of preeclampsia in women with low dietary calcium intake; in women at high risk with adequate dietary calcium, the benefit is smaller but still clinically meaningful; calcium supplementation is started at 10–12 weeks.
E) Low-dose aspirin 81–150 mg daily started before 16 weeks of gestation — aspirin is the best-evidenced pharmacological intervention for preeclampsia prevention in high-risk women; it inhibits platelet COX-1, reducing thromboxane A2-mediated platelet aggregation and vasoconstriction in placental spiral arteries; the benefit requires early initiation (before 16 weeks) to influence trophoblastic invasion during placentation; a prior history of preeclampsia is a primary high-risk indication for aspirin prophylaxis per ACOG and ISSHP guidelines.

ANSWER: E

Rationale:

Low-dose aspirin started before 16 weeks is the best-evidenced pharmacological intervention for preeclampsia prevention in high-risk women. Two or more prior preeclampsia events constitute a very high-risk indication — the cumulative recurrence risk approaches 25–40% with two prior events. The mechanism is COX-1-mediated reduction of platelet thromboxane A2, shifting the thromboxane-prostacyclin balance toward vasodilation and reducing platelet aggregation in the spiral arteries undergoing trophoblastic invasion. Timing is critical: aspirin started before 16 weeks (optimally 12–16 weeks) affects the second wave of trophoblastic invasion that establishes placental vascular architecture; aspirin started after 20 weeks provides negligible preventive benefit. Meta-analyses including the ASPRE trial demonstrate a 60–80% relative risk reduction in early-onset preeclampsia with aspirin started before 16 weeks in high-risk women. ACOG and ISSHP both recommend aspirin for women with prior preeclampsia.

Option A: Option A is incorrect because oral magnesium supplementation is not an established pharmacological prevention for preeclampsia — magnesium sulfate is used therapeutically for seizure prophylaxis, not prophylactically to prevent preeclampsia; there is no established 35% reduction in preeclampsia incidence with oral magnesium.
Option B: Option B is incorrect because LMWH prophylaxis for preeclampsia prevention is not established in non-thrombophilic women — its role is in women with antiphospholipid syndrome or inherited thrombophilias where placental thrombosis contributes to the pathology; for the general high-risk preeclampsia population, aspirin is the evidence-based intervention.
Option C: Option C is incorrect because pravastatin for preeclampsia prevention is investigational — some promising data exist from small trials but statin use in pregnancy is not currently recommended (statins are potentially teratogenic in animal models and not yet established as safe and effective for this indication); a 40% reduction claim is not established.
Option D: Option D is incorrect because calcium supplementation's evidence for preeclampsia prevention is strongest in populations with low dietary calcium intake — in regions with adequate calcium intake, the benefit is substantially smaller; it is not the primary evidence-based pharmacological prevention for a high-risk woman in an adequate-nutrition setting; and aspirin has a much stronger and more consistent evidence base for high-risk women.

6. A 35-year-old woman at 36 weeks gestation with preeclampsia is receiving IV labetalol and IV magnesium sulfate. Her BP is now 138/86 mmHg (adequately controlled). The magnesium infusion is running at 1 g/hour. Her urine output over the past 2 hours has been 18 mL/hour (oliguria, below the 25 mL/hour threshold). Her serum magnesium level 1 hour ago was 6.2 mEq/L and patellar reflexes are intact. What is the most appropriate management of the oliguria in this context?

A) Administer IV furosemide 40 mg immediately — aggressive diuresis is mandatory for oliguria in preeclampsia to prevent pulmonary edema; loop diuretics are the standard treatment for preeclampsia-related oliguria.
B) Increase IV fluid rate to 200 mL/hour of normal saline — volume expansion corrects the oliguria in preeclampsia by restoring reduced intravascular volume; aggressive fluid resuscitation is required before any other intervention.
C) Reduce the magnesium sulfate infusion rate from 1 g/hour to 0.5–0.75 g/hour — with urine output below 25 mL/hour, magnesium renal clearance is proportionally reduced and the current infusion rate risks accumulation above the therapeutic range; this is the pharmacologically appropriate response to oliguria on magnesium; continue to monitor patellar reflexes and respiratory rate closely; recheck magnesium level in 1 hour.
D) Stop the magnesium infusion entirely and do not restart — oliguria at any level is an absolute contraindication to continuing magnesium sulfate in preeclampsia; restarting magnesium after oliguria resolves carries too great an accumulation risk.
E) Administer calcium gluconate 1 g IV preemptively — oliguria predicts impending magnesium toxicity and prophylactic calcium gluconate prevents the anticipated toxicity before clinical signs appear; this is standard practice in preeclampsia with oliguria on magnesium.

ANSWER: C

Rationale:

Oliguria in a patient on magnesium sulfate is a pharmacokinetically critical finding requiring infusion rate reduction, not complete cessation. Magnesium is eliminated almost entirely by renal glomerular filtration — urine output below 25 mL/hour indicates reduced renal magnesium clearance. At a standard maintenance infusion rate of 1 g/hour with reduced clearance, plasma magnesium accumulates even though the input rate is unchanged. The appropriate response is a proportional reduction in the maintenance infusion rate (to 0.5–0.75 g/hour) to reduce magnesium input to match the reduced clearance capacity. The current clinical picture — level 6.2 mEq/L (within therapeutic range), patellar reflexes intact, BP controlled — indicates the patient is not yet showing toxicity. Close monitoring (hourly patellar reflexes, respiratory rate) must continue with heightened vigilance. Calcium gluconate remains at the bedside. The magnesium infusion is not stopped entirely unless clinical toxicity develops.

Option A: Option A is incorrect because aggressive IV furosemide for oliguria in preeclampsia is not the standard approach — preeclampsia-related oliguria is typically from intravascular volume depletion and reduced renal perfusion from vasoconstriction; forcing diuresis with loop diuretics in an already intravascularly depleted patient can worsen hemodynamics; and furosemide does not address the magnesium accumulation risk.
Option B: Option B is incorrect because aggressive fluid resuscitation (200 mL/hour) in preeclampsia carries significant risk of pulmonary edema — preeclampsia causes endothelial dysfunction that increases vascular permeability; fluid administered to expand intravascular volume leaks into the extravascular space and causes pulmonary edema; cautious fluid management (not aggressive resuscitation) is the approach in preeclampsia oliguria.
Option D: Option D is incorrect because stopping magnesium entirely is an overreaction when the clinical picture does not show toxicity — the patient has intact reflexes and a therapeutic level; infusion rate reduction (not cessation) is proportionate.
Option E: Option E is incorrect because prophylactic calcium gluconate is not standard practice for oliguria alone in the absence of clinical toxicity signs — calcium gluconate is the antidote for magnesium toxicity (absent reflexes, respiratory depression), not a prophylactic agent; administering it preemptively would reverse therapeutic seizure prophylaxis.

7. A woman with chronic hypertension on methyldopa 500 mg three times daily and long-acting nifedipine 60 mg daily presents at 34 weeks gestation with BP 156/100 mmHg — above target. She tolerates her current regimen well but her physician wants to add a third agent. Which of the following additions is most pharmacologically appropriate in this context?

A) Add labetalol 100 mg twice daily — labetalol provides complementary alpha-1 and beta-adrenergic blockade to the central alpha-2 agonism of methyldopa and the arteriolar vasodilation of nifedipine; the combination of three distinct BP-lowering mechanisms addresses the uncontrolled hypertension; all three agents have established pregnancy safety profiles; the combination has been used clinically and is pharmacologically rational.
B) Add losartan 25 mg daily — at low doses, ARBs are safe as a third agent in the third trimester; the fetal RAAS toxicity is primarily associated with high-dose ARBs in the second trimester.
C) Add hydrochlorothiazide 25 mg daily — thiazide diuretics are the preferred third agent in pregnancy when two antihypertensives have failed to achieve target; at this dose in the third trimester, the volume depletion risk to the fetus is acceptable.
D) Add spironolactone 12.5 mg daily — at this low dose, spironolactone's anti-androgenic properties are below the threshold for fetal harm; its aldosterone-blocking mechanism addresses the hyperaldosteronism of the third trimester that is contributing to BP elevation.
E) Add IV hydralazine 5 mg every 4 hours as a scheduled inpatient treatment — oral hydralazine is insufficiently reliable for third-trimester BP control; scheduled IV hydralazine achieves more consistent plasma levels and is the standard approach for three-drug resistant hypertension in pregnancy.

ANSWER: A

Rationale:

Adding labetalol to methyldopa and nifedipine is the most pharmacologically appropriate third agent in this context. The three agents work through three distinct mechanisms: methyldopa (central alpha-2 agonism reducing sympathetic outflow), nifedipine (L-type calcium channel blockade reducing SVR), and labetalol (peripheral alpha-1 blockade reducing SVR plus beta-1 blockade reducing cardiac output, without reflex tachycardia from the combined alpha-beta mechanism). All three have established first-line safety profiles in pregnancy. The combination is pharmacologically rational and has clinical use in resistant or difficult-to-control hypertension in pregnancy. Labetalol at 100 mg twice daily starts at the lower end of the therapeutic range and can be titrated.

Option B: Option B is incorrect because ARBs are absolutely contraindicated in all trimesters at any dose — there is no safe low dose of an ARB in pregnancy; fetal RAAS toxicity is not dose-stratified in a way that makes low-dose third-trimester ARBs safe.
Option C: Option C is incorrect because HCTZ 25 mg is not the preferred third agent in pregnancy — new thiazide initiation is avoided during pregnancy due to theoretical placental perfusion concerns; and at 25 mg in the third trimester the metabolic and volume effects are not trivially "acceptable."
Option D: Option D is incorrect because spironolactone is avoided during pregnancy regardless of dose — the anti-androgenic concern from animal data applies at therapeutic doses; a "below-threshold" safe dose of spironolactone during pregnancy has not been established.
Option E: Option E is incorrect because oral hydralazine is available and can be used as a second-line oral agent — IV hydralazine is reserved for acute severe hypertension (IV access, emergency setting), not for scheduled outpatient or inpatient management of non-severe hypertension; scheduled IV hydralazine every 4 hours is not standard practice for chronic management.

8. A 32-year-old woman at 25 weeks gestation develops acute severe hypertension (BP 174/116 mmHg) in an outpatient obstetric clinic. She has no IV access and the clinic has no IV medications. Which of the following is the most appropriate immediate pharmacological intervention?

A) Call an ambulance and defer all pharmacological treatment until IV access is established in the emergency department — oral agents are not appropriate for BP above 160/110 mmHg in pregnancy; only IV agents should be used for this level of hypertension.
B) Administer sublingual nifedipine 10 mg — the sublingual route achieves the fastest onset for acute severe hypertension in a clinic setting without IV access; the risk of precipitous BP drop from sublingual administration is acceptable when BP is this high.
C) Administer oral methyldopa 750 mg — methyldopa is the fastest-acting oral antihypertensive available in pregnancy; its onset of 30–45 minutes is equivalent to sublingual nifedipine and is the agent of choice when IV access is unavailable.
D) Administer oral immediate-release nifedipine 10 mg swallowed (not sublingual) — swallowed oral nifedipine IR achieves onset within 20–30 minutes; it is specifically listed by ACOG as an acceptable first-line agent for acute severe hypertension in pregnancy when IV access is unavailable; a repeat dose of 10 mg can be given after 20–30 minutes if BP remains ≥160/110 mmHg; arrange urgent transfer to an obstetric unit simultaneously.
E) Administer oral labetalol 400 mg — the highest oral labetalol dose achieves the most rapid onset; oral labetalol at this dose is equivalent to IV labetalol in terms of BP reduction speed and is the preferred agent when IV access is unavailable for acute severe hypertension in pregnancy.

ANSWER: D

Rationale:

Oral immediate-release nifedipine 10 mg swallowed is specifically listed by ACOG as an acceptable and appropriate intervention for acute severe hypertension in pregnancy when IV access is not immediately available. Swallowed oral nifedipine IR undergoes gastric absorption with peak plasma levels and BP reduction occurring within 20–30 minutes — rapid enough to be clinically meaningful within the 30–60 minute treatment window for severe-range hypertension. The dose is 10 mg orally (swallowed), with a repeat dose of 10 mg after 20–30 minutes if BP remains above the severe threshold, up to a maximum of 30 mg per episode. Simultaneously, urgent transfer to an obstetric unit with IV access capability and monitoring equipment should be arranged. Sublingual nifedipine is specifically not recommended — the oral swallowed route is the specified route.

Option A: Option A is incorrect because deferring all pharmacological treatment while awaiting IV access misses the 30–60 minute treatment window for acute severe hypertension in pregnancy — oral swallowed nifedipine provides an effective and ACOG-endorsed alternative that can be administered immediately in a clinic setting.
Option B: Option B is incorrect because sublingual nifedipine is specifically not recommended in pregnancy — it produces an unpredictable, potentially precipitous BP drop that can cause acute placental hypoperfusion; the oral swallowed route is the specified and safe route.
Option C: Option C is incorrect because methyldopa has an onset of action of 4–6 hours after oral dosing — it is not a fast-acting agent and is entirely inappropriate for acute severe hypertension management; its role is chronic management, not acute intervention.
Option E: Option E is incorrect because oral labetalol at 400 mg is not equivalent to IV labetalol for acute severe hypertension — oral absorption takes 20–60 minutes to achieve meaningful plasma levels and the highest oral dose does not produce the same rapid pharmacodynamic effect as IV administration; oral labetalol can be used for maintenance but is not the preferred acute agent in this setting.

9. A 28-year-old primiparous woman is 5 days postpartum after delivery at 39 weeks. Her pregnancy was complicated by gestational hypertension that was not treated (BP remained below 160/110 mmHg throughout). She was discharged on postpartum day 2 with instructions to monitor BP at home. She calls the obstetric unit reporting a BP of 168/110 mmHg at home, severe headache, and visual blurring. She has no prior antihypertensive medications. Which of the following is the most appropriate immediate instruction?

A) Advise the patient to take ibuprofen 600 mg for the headache and recheck BP in 2 hours — NSAIDs are safe postpartum and provide rapid headache relief; if the BP does not improve within 2 hours she should attend the emergency department.
B) Instruct the patient to come to the emergency department immediately — BP of 168/110 mmHg with severe headache and visual symptoms in the postpartum period meets criteria for severe postpartum preeclampsia/hypertension and constitutes a neurological emergency; she requires evaluation, IV or oral antihypertensives, assessment for eclampsia, and possible magnesium sulfate; the symptoms of severe headache and visual disturbance are neurological warning signs of impending eclampsia up to 4 weeks postpartum.
C) Advise the patient to take two acetaminophen tablets and lie in a dark room — postpartum severe headache with hypertension is most likely migraine triggered by the hormonal changes of delivery; anti-hypertensive treatment can be deferred until the headache resolves and a more reliable BP measurement can be obtained.
D) Prescribe oral labetalol 200 mg by phone without seeing the patient — home management with oral labetalol is appropriate for postpartum BP of 168/110 mmHg; the patient does not need emergency department evaluation and can follow up in one week.
E) Advise the patient that her BP will normalize within 48 hours as the postpartum fluid mobilization completes — reassurance is the appropriate management for BP elevation in the first week postpartum; antihypertensives at this stage would cause excessive BP lowering that risks postpartum stroke.

ANSWER: B

Rationale:

This patient requires immediate emergency department evaluation. Her presentation — BP 168/110 mmHg with severe headache and visual blurring, 5 days postpartum — meets criteria for severe postpartum hypertension with neurological warning signs of impending eclampsia. Postpartum eclampsia can occur up to 4 weeks after delivery (most commonly within the first 7 days), and the combination of severe-range hypertension with neurological symptoms (headache, visual disturbance) in the postpartum period is a clinical emergency. She requires: immediate evaluation; IV or oral antihypertensive therapy to bring BP below the severe threshold within 30–60 minutes; assessment for preeclampsia features (proteinuria, thrombocytopenia, liver enzymes) that may have developed; and consideration of magnesium sulfate for seizure prophylaxis if severe preeclampsia is confirmed. Phone management without evaluation is unacceptable given the neurological symptoms.

Option A: Option A is incorrect because NSAIDs — including ibuprofen — are specifically contraindicated in postpartum hypertension; NSAIDs blunt antihypertensive efficacy, promote sodium retention, and raise BP, potentially worsening a hypertensive crisis; and deferring evaluation for 2 hours in a patient with severe-range BP and neurological symptoms is dangerous.
Option C: Option C is incorrect because severe headache with BP 168/110 mmHg and visual symptoms in the postpartum period should not be attributed to migraine without evaluation — migraine does not explain the concurrent severe hypertension; this presentation requires exclusion of eclampsia.
Option D: Option D is incorrect because prescribing oral labetalol by phone without evaluation is inadequate for a patient with severe-range BP and neurological symptoms — this presentation requires clinical evaluation for proteinuria, laboratory assessment for HELLP, and possibly magnesium sulfate.
Option E: Option E is incorrect because BP of 168/110 mmHg is not a self-resolving postpartum fluid shift finding — it meets the severe hypertension threshold requiring pharmacological intervention; reassurance alone in a patient with neurological symptoms is potentially fatal.

10. A woman with preeclampsia at 34 weeks gestation is receiving oral labetalol 300 mg three times daily and long-acting nifedipine 60 mg daily. Her BP is 146/92 mmHg — within the pregnancy-acceptable range. She is admitted for expectant management. Her obstetrician asks the clinical pharmacist whether the labetalol dose can be safely increased further if BP rises. The pharmacist reviews labetalol dosing limits in pregnancy. Which of the following correctly describes the maximum safe oral labetalol dose in pregnancy?

A) The maximum oral labetalol dose in pregnancy is 400 mg twice daily — above this dose, fetal beta-2 blockade from transplacental labetalol transfer causes severe bronchospasm in the neonate at delivery; doses above 400 mg twice daily require prophylactic neonatal bronchodilators.
B) The maximum oral labetalol dose in pregnancy is 200 mg twice daily — above this dose, labetalol's alpha-1 blocking component causes excessive uteroplacental vasodilation that paradoxically reduces fetal blood flow by lowering placental vascular resistance below the critical threshold for fetal perfusion.
C) The maximum oral labetalol dose in pregnancy is 300 mg once daily — labetalol's non-selective beta-blockade at higher doses produces additive cardiovascular effects with nifedipine that risk fatal maternal bradycardia; dose escalation above 300 mg once daily requires ECG monitoring.
D) Labetalol has no established maximum oral dose in pregnancy — it is titrated to BP response without any pharmacological dose ceiling; doses above 2,400 mg/day have been used without documented adverse maternal or fetal outcomes.
E) The maximum recommended oral labetalol dose in pregnancy is 2,400 mg per day in divided doses (e.g., 400–600 mg four times daily) — this represents the upper limit studied and used clinically; at the current total daily dose of 900 mg daily (300 mg three times daily), there is pharmacological room for dose escalation if BP rises; neonatal monitoring for bradycardia and hypoglycemia should be arranged for the newborn given the beta-blocker exposure.

ANSWER: E

Rationale:

Oral labetalol's maximum recommended dose in pregnancy is 2,400 mg per day in divided doses — this is the ceiling dose referenced in obstetric pharmacology references and represents the upper limit of what has been studied and used clinically. This patient's current total daily dose of 900 mg (300 mg three times daily) leaves substantial pharmacological room for dose escalation if needed. Common oral dosing strategies in pregnancy use 100–400 mg two to four times daily, with total daily doses ranging up to 2,400 mg. Regardless of dose, neonatal monitoring is required for any newborn exposed to labetalol: beta-blockade crosses the placenta and can cause neonatal bradycardia and neonatal hypoglycemia (beta-2 blockade in the neonate impairs glycogenolysis).

Option A: Option A is incorrect because the maximum oral labetalol dose in pregnancy is 2,400 mg/day, not 400 mg twice daily (800 mg/day); and the concern about neonatal bronchospasm from transplacental labetalol is not the dose-limiting toxicity requiring prophylactic bronchodilators — neonatal bradycardia and hypoglycemia are the monitoring concerns.
Option B: Option B is incorrect because labetalol's alpha-1 blocking component does not cause excessive uteroplacental vasodilation that paradoxically reduces fetal perfusion — alpha-1 blockade dilates maternal arterioles reducing SVR; it does not selectively vasodilate the placental bed; and 200 mg twice daily (400 mg/day) is a very conservative total dose well below the 2,400 mg maximum.
Option C: Option C is incorrect because the maximum is 2,400 mg/day in divided doses, not 300 mg once daily; and combined bradycardia risk with nifedipine from non-selective beta blockade is not an established pharmacological ceiling requiring ECG monitoring at doses above 300 mg once daily.
Option D: Option D is incorrect because labetalol does have an established maximum dose of 2,400 mg/day in pregnancy — stating there is "no maximum" is pharmacologically imprecise; doses above this ceiling are not typically used.

11. A woman delivers at 37 weeks after a pregnancy complicated by preeclampsia with severe features. She is discharged on postpartum day 4 on labetalol 200 mg twice daily. At her 6-week postpartum visit, her BP is 148/94 mmHg. Before pregnancy her BP was 116/72 mmHg with no antihypertensives. Which of the following best describes the long-term management implications of this persistent elevated postpartum BP?

A) The elevated BP at 6 weeks postpartum is expected physiological postpartum hypertension — it resolves in all women by 12 weeks postpartum; labetalol should be continued until 12 weeks and then stopped; no further cardiovascular follow-up is needed.
B) The elevated BP at 6 weeks postpartum confirms that this woman has developed new chronic hypertension — she should be transitioned to a long-term antihypertensive regimen with a RAAS inhibitor as first-line because her preeclampsia history indicates underlying RAAS dysregulation; she requires no additional cardiovascular screening.
C) The elevated BP at 6 weeks postpartum in a woman with previously normal preconception BP suggests new onset of chronic hypertension following preeclampsia — this is consistent with the 4-fold increased lifetime risk of hypertension after preeclampsia; she should continue antihypertensive therapy, be informed of her substantially elevated long-term cardiovascular risk (2-fold increased risk of cardiovascular disease and stroke, 4-fold increased risk of chronic hypertension, significantly elevated CKD risk), and be offered a comprehensive cardiovascular risk screening plan including annual BP monitoring, lipid assessment, and glucose testing; the antihypertensive can be transitioned to a standard evidence-based agent (RAAS inhibitor if appropriate, or CCB/ARB based on individual profile) now that pregnancy is over.
D) Persistent elevated BP at 6 weeks postpartum after preeclampsia indicates concealed renal artery stenosis — preeclampsia is the presenting manifestation of bilateral renovascular disease in 40% of cases; urgent renal Doppler ultrasound and possible renin-angiotensin profiling are required before selecting an antihypertensive.
E) The elevated BP at 6 weeks postpartum is within normal postpartum variation — no antihypertensives are needed because BP above 140/90 mmHg is physiological for up to 3 months postpartum in women who had preeclampsia; labetalol should be stopped and BP rechecked at 6 months.

ANSWER: C

Rationale:

A woman with previously normal BP (116/72 mmHg before pregnancy) who has elevated BP at 6 weeks postpartum (148/94 mmHg) after severe preeclampsia presents a management challenge that encompasses both immediate care and long-term cardiovascular risk. BP elevated at 6 weeks postpartum — beyond the physiological fluid mobilization window of the first 1–2 weeks — suggests new-onset chronic hypertension, not physiological postpartum variation. This is consistent with the well-documented long-term cardiovascular legacy of preeclampsia: women who have had preeclampsia face a 4-fold increased lifetime risk of developing chronic hypertension, a 2-fold increased risk of cardiovascular disease and stroke, and a significantly elevated risk of CKD. These risks are not transient — they persist for decades. Immediate management: continue antihypertensive therapy with an appropriate long-term agent (now that pregnancy constraints are lifted, a RAAS inhibitor may be appropriate if she has proteinuria or other compelling indications, or an ARB/CCB/ACEi based on her profile and whether she plans future pregnancies); consider switching from labetalol to a more convenient once-daily long-term agent. Long-term management: annual BP monitoring, lipid screening, and glucose testing; counseling about cardiovascular risk reduction through lifestyle modification; coordination with primary care for ongoing surveillance.

Option A: Option A is incorrect because elevated BP at 6 weeks postpartum is not guaranteed to resolve by 12 weeks in all women — many women with postpartum hypertension after preeclampsia have persistent or permanent chronic hypertension; and the long-term cardiovascular risk requires ongoing surveillance.
Option B: Option B is incorrect because a RAAS inhibitor is not automatically the first-line choice — it would be preferred if she has proteinuria or CKD features, but the antihypertensive selection should be individualized; and cardiovascular screening is specifically indicated given the elevated long-term risk.
Option D: Option D is incorrect because preeclampsia is not a presenting manifestation of bilateral renovascular disease in 40% of cases — this is a fabricated statistic; renal artery stenosis is not the presumed diagnosis in a woman with postpartum persistent hypertension after preeclampsia.
Option E: Option E is incorrect because BP above 140/90 mmHg at 6 weeks postpartum is not physiological variation in women with prior preeclampsia — it represents elevated BP requiring treatment and investigation; stopping antihypertensives without evaluation is clinically inappropriate.